PGR and breast carcinoma: In the case of breast cancer, therapeutics that bind and inhibit the function of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) have led to enhanced survival rates of patients whose tumors are characterized as ER positive, PR positive, and HER2 amplified, respectively [4].